The Commonwealth of Kentucky, in collaboration with the University of Louisville Christina Lee Brown Envirome Institute and the Louisville Healthcare CEO Council, is launching a groundbreaking initiative with three large Kentucky hospital systems – Baptist Health, Norton Healthcare and UofL Health. The purpose is to help health care workers understand whether they were unknowingly exposed to COVID-19, to determine how much immunity was generated by such exposure, and to identify those with the best immune responses as donors of high-quality plasma for rescue treatment of patients with advanced COVID-19.

In addition, these data will be informative as scientists worldwide are working to determine whether quantitative antibody measurements can be used to predict immunity in the overall workforce. This program represents a unique alliance between government and otherwise competing private groups in order to address an unprecedented crisis.

Testing will begin with high-risk personnel in Kentucky, starting with the health care workforce. As the process is scaled up it will be made available to other essential workers. There will be three steps of testing:

• First, a point-of-care test will provide a yes or no answer on the presence of antibodies.
• In a second step, positive blood will then be assayed for the amount of antibodies present in the blood.
• Finally, in patients with high amounts, the neutralizing power of the antibodies will be evaluated.

The University of Louisville Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), has established a high-throughput, real-time assay for SARS-CoV-2 antibodies that will be utilized and CPM will use their renowned Bio Safety Level 3 facility to test for the neutralizing activity of the antibodies.

“The University of Louisville is committed to addressing all forms of health,” said Neeli Bendapudi, President of the University of Louisville. “We are uniquely positioned to play a key role in this effort because of our talented researchers at CPM and our UofL Regional Biocontainment Laboratory, which allows us to establish the very best donors of plasma for patients.”

This unprecedented collaboration of the public and private sector has already secured private donations of $1.75 million in the form of a challenge grant to build community-wide coalition of philanthropic support, which will allow the program to scale more quickly and save more lives. (Click here for more details on how you can help).

“America and Louisville need more and advanced COVID-19 testing now. I am excited about this ambitious project and its potential to provide useful data for the recovery of our community. Louisville’s team of cutting-edge scientists represents the best of who we are as Louisvillians – compassionate, smart and entrepreneurial,” said Louisville Mayor Greg Fischer.

“This is exactly the kind of collaboration that Kentucky is poised to enable,” said Dr. Cedric Francois, CEO of Apellis Pharmaceuticals and LHCC board member. “We have the infrastructure in our commonwealth to quickly bring this revolutionary technology together by leveraging the great work already being done with the health care stakeholders, such as Norton Healthcare’s convalescent plasma program, and the extensive work that had already been done to start their antibody serology testing to improve Kentucky’s response and recovery to the COVID-19 pandemic and be a model for the rest of the nation.”

“This model for testing is exciting and it is our hope that antibody measurements can be used to predict immunity,” said Kentucky Governor Andy Beshear. “If so, it will be a critical tool in the reopening of Kentucky’s economy.”